Skip to main content

RETRACTION article

Front. Surg., 11 October 2023
Sec. Surgical Oncology
Volume 10 - 2023 | https://doi.org/10.3389/fsurg.2023.1307330

Retraction: Longitude variation of the microRNA-497/FGF-23 axis during treatment and its linkage with neoadjuvant/adjuvant trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients

This article is a retraction of:

  1. RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients

    1. Read original article
\r\nFrontiers Editorial Office \r\nFrontiers Editorial Office*

A Retraction of the Original Research Article

Longitude variation of the microRNA-497/FGF-23 axis during treatment and its linkage with neoadjuvant/adjuvant trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients

By Liu H, Hu X, Wang L, Du T, Feng J, Li M, Liu L and Liu X (2022) Front. Surg. 9:862617. doi: 10.3389/fsurg.2022.862617

The journal and Chief Editors retract the 11 May 2022 article cited above.

This article is retracted by Frontiers. The publisher has discovered that the authors provided false information for the peer-review process. As the scientific integrity of the article cannot be guaranteed, and adhering to the recommendations of the Committee on Publication Ethics (COPE), the publisher therefore retracts the article.

The authors have not responded to this retraction.

This retraction was approved by the Chief Editors of Frontiers in Surgery and the Chief Executive Editor of Frontiers.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Citation: Frontiers Editorial Office (2023) Retraction: Longitude variation of the microRNA-497/FGF-23 axis during treatment and its linkage with neoadjuvant/adjuvant trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients. Front. Surg. 10:1307330. doi: 10.3389/fsurg.2023.1307330

Received: 4 October 2023; Accepted: 4 October 2023;
Published: 11 October 2023.

Approved by: Dennis Paul Orgill, Harvard Medical School, United States

© 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office research.integrity@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.